Inventor · disambiguated record
Elena Burova
Also filed as: BUROVA ELENA
18 granted patents·11 pending applications·249 citations·filing 2014–2024
94Inventor score
Top patents by PatentIndex Score
29 records- 0198US9987500B2Human antibodies to PD-1REGENERON PHARMA·Filed 2015·Granted Jun 5, 2018·126 cites·10 claims
- 0298US9938345B2Human antibodies to PD-L1REGENERON PHARMA·Filed 2015·Granted Apr 10, 2018·37 cites·8 claims
- 0396US10358495B2Anti-LAG3 antibodies and uses thereofREGENERON PHARMA·Filed 2016·Granted Jul 23, 2019·47 cites·18 claims
- 0493US11117970B2Human antibodies to PD-L1REGENERAN PHARMACEUTICALS INC·Filed 2018·Granted Sep 14, 2021·4 cites·15 claims
- 0591US10306874B2Non-human animals having a humanized lymphocyte-activation gene 3REGENERON PHARMA·Filed 2016·Granted Jun 4, 2019·4 cites·10 claims
- 0689US10737113B2Human antibodies to PD-1REGENERON PHARMA·Filed 2018·Granted Aug 11, 2020·2 cites·18 claims
- 0789US10390522B2Non-human animals having a humanized programmed cell death 1 geneREGENERON PHARMA·Filed 2015·Granted Aug 27, 2019·6 cites·15 claims
- 0889US9968674B2Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibodyREGENERON PHARMA·Filed 2014·Granted May 15, 2018·10 cites·16 claims
- 0988US11692032B2Anti-LAG3 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jul 4, 2023·3 cites·28 claims
- 1087US2024397919A1Non-human animals having a humanized lymphocyte-activation gene 3REGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1186US9913461B2Genetically modified mouse whose genome comprises a humanized CD274 geneREGENERON PHARMA·Filed 2015·Granted Mar 13, 2018·4 cites·19 claims
- 1286US2024389563A1Genetically modified mouse that expresses humanized pd1 and pd-l1 proteinsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1385US10881086B2Genetically modified mouse whose genome comprises a humanized CD274 geneREGENERON PHARMA·Filed 2018·Granted Jan 5, 2021·2 cites·10 claims
- 1485US10844137B2Anti-CTLA-4 antibodies and uses thereofREGENERON PHARMA·Filed 2018·Granted Nov 24, 2020·2 cites·20 claims
- 1584US2025092139A1Human antibodies to pd-l1REGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1684US2024316361A1Human Antibodies To PD-1REGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1783US11684050B2Non-human animals having a humanized programmed cell death 1 geneREGENERON PHARMA·Filed 2019·Granted Jun 27, 2023·1 cites·14 claims
- 1883US2025122307A1Anti-CTLA-4 Antibodies and Uses ThereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1982US11102961B2Non-human animals having a humanized lymphocyte-activation gene 3REGENERON PHARMA·Filed 2019·Granted Aug 31, 2021·1 cites·18 claims
- 2082US2024298619A1Non-human animals having a humanized programmed cell death 1 geneREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2177US12096754B2Non-human animals having a humanized lymphocyte-activation gene 3REGENERON PHARMA·Filed 2021·Granted Sep 24, 2024·0 cites·9 claims
- 2277US2024166740A1Anti-lag3 antibodies and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2374US2021380702A1Human antibodies to pd-l1REGENERON PHARMA·Filed 2021·Application pending·0 cites
- 2473US12089575B2Genetically modified mouse that expresses humanized PD1 and PD-L1 proteinsREGENERON PHARMA·Filed 2020·Granted Sep 17, 2024·0 cites·7 claims
- 2570US12024570B2Anti-CTLA-4 antibodies and uses thereofREGENERON PHARMA·Filed 2020·Granted Jul 2, 2024·0 cites·21 claims
- 2669US2020330794A1Human antibodies to pd-1REGENERON PHARMA·Filed 2020·Application pending·0 cites
- 2763US2023235089A1Methods for Treating Cancer with Bispecific Anti-CD3 x MUC16 Antibodies and Anti-CTLA-4 AntibodiesREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2860US2018206462A1Non-human animals having a humanized programmed cell death 1 geneREGENERON PHARMA·Filed 2018·Application pending·0 cites
- 2958US10532096B2Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibodyREGENERON PHARMA·Filed 2018·Granted Jan 14, 2020·0 cites·32 claims
Join the waitlist — get patent alerts
Get an alert when Elena Burova files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →